Trends in the Oncology Pipeline
Global spending on cancer medications in 2022 was $196 billion, and that number is expected to jump to $375 billion by 2027, according to...
Optimizing the Approach to Value Assessment
When making coverage and reimbursement decisions, it is essential to have a complete view and a comprehensive methodology to assess value. A presentation at...
Study: ICER Rejects Vast Majority of Evidence When Determining Unsupported Price Increases
New research presented at AMCP Nexus 2023 shows that the Institute for Clinical and Economic Review (ICER) rejects the vast majority (97%) of evidence...